Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Depotech(depo) -- Ignore unavailable to you. Want to Upgrade?

To: John McCarthy who wrote (646)	12/22/1997 9:49:00 AM
From: chirodoc	Read Replies (1) \| Respond to of 887

...another story of the debacle du jour DEPOTECH (DEPO) 4 3/16 -8 13/16. Back in the good old days (3 months ago), DEPO shares would have probably started to rebound by now, as traders and devout shareholders attempted to take advantage of the panic by buying into the weakness. But, in this new environment, losers get dismembered and are left with little chance for an intraday or next day bounce. However, you should decide for yourself whether DEPO looks attractive as a high-risk/high-reward, trading play. DEPO shares have fallen 68% on the session following news the Oncologic Drugs Advisory Committee to the U.S. Food and Drug Administration (FDA) has declined to recommend approval of DepoCyt, an anti-cancer agent, for use in patients with neoplastic meningitis (NM) arising from solid tumors. End of story, right; after all this money-losing, anemic revenue producing drug-delivery company had led investors to believe that DepoCyt would be a star. Well, according to DepoTech, it will work closely with the FDA to define a path forward, including submitting additional data for supplemental FDA review. Moreover, the company has another DepoCyt application that is said to be a strong candidate for approval. Hence, where there is hope, no matter how small, there is usually opportunity.

To: John McCarthy who wrote (646)	12/23/1997 5:40:00 AM
From: ForYourEyesOnly	Read Replies (2) \| Respond to of 887

Financial Fundamentals: DEPO's share price has plummeted to below $4 per share. Is this warranted? According to the financial info on Yahoo: DEPO Book value per share: $3.18 DEPO Cash per share: $2.45 Surely the DEPO foam and the DEPO morphine must be worth something per share? I bought at $14 and I am very unhappy. I was thinking of "taking my lumps", but looking at the above information makes me think that if DEPO is able to produce ANY good news, it should be worth much more than $4 per share. If there are any that disagree, please share your ideas. I did not like the ride from $14 to $4, but I would also like to avoid a ride from $4 to $1. Good luck and keep the ideas coming.... THC